Untitled Letters 2023
These letters are supplied by the CDER Freedom of Information Office and only covers Office of Prescription Drug Promotion's untitled letters. The agency may have redacted or edited some of the letters to remove confidential information.
Office of Prescription Drug Promotion Untitled Letter and Promotional Material
Company / Individual | Product / Issue | Issued Date |
---|---|---|
Xeris Pharmaceuticals, Inc.
|
NDA 214133 RECORLEV (levoketoconazole) tablets, oral | 6/07/2023 |
Exeltis USA Inc.
|
NDA 211367 SLYND (drospirenone) tablets, oral | 8/11/2023 |